Covered recipient · General Payments record
SIDDHARTHA H DEVARAKONDA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$125,021.17
124 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $63,270.00 | 23 |
| Consulting Fee | $51,168.25 | 29 |
| Travel and Lodging | $6,394.09 | 28 |
| Food and Beverage | $2,876.33 | 43 |
| Honoraria | $1,312.50 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $53,179.85 | 55 |
| AstraZeneca Pharmaceuticals LP | $37,653.13 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24,525.15 | 18 |
| E.R. Squibb & Sons, L.L.C. | $3,080.00 | 2 |
| Eli Lilly and Company | $1,663.00 | 2 |
| CATALYST PHARMACEUTICALS, INC. | $1,479.83 | 3 |
| Amgen Inc. | $1,384.58 | 2 |
| Daiichi Sankyo Inc. | $1,186.89 | 7 |
| Acrotech Biopharma Inc. | $600.00 | 1 |
| Tempus AI, Inc | $147.24 | 2 |
| Mirati Therapeutics, Inc. | $121.50 | 1 |
Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SIDDHARTHA H DEVARAKONDA
NPI 1487932398 · CMS profile ID 113148
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
SEATTLE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- SIDDHARTHA H DEVARAKONDA, NPI 1487932398, CMS profile ID 113148, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–124 of 124 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487932398?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
124 matching records · $125,021.17 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–124 of 124.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $380.04 | 04/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206367369 | CMS |
| AstraZeneca Pharmaceuticals LP | $279.72 | 04/03/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206415685 | CMS |
| AstraZeneca Pharmaceuticals LP | $135.00 | 04/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206748931 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.13 | 03/31/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206520732 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,480.00 | 03/28/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223049612 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $740.00 | 03/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223049616 | CMS |
| Janssen Biotech, Inc. | $1,110.00 | 03/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175332218 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,340.00 | 03/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206734171 | CMS |
| Janssen Biotech, Inc. | $1,250.00 | 03/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175326498 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,480.00 | 03/14/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1223049614 | CMS |
| Janssen Biotech, Inc. | $555.00 | 03/03/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175331329 | CMS |
| Janssen Biotech, Inc. | $3,607.50 | 02/19/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175325874 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,350.00 | 02/13/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206861051 | CMS |
| AstraZeneca Pharmaceuticals LP | $70.52 | 02/12/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207260483 | CMS |
| Janssen Biotech, Inc. | $143.68 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175326240 | CMS |
| Janssen Biotech, Inc. | $6.61 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175332434 | CMS |
| Janssen Biotech, Inc. | $171.11 | 02/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175332879 | CMS |
| Janssen Biotech, Inc. | $4,125.00 | 02/03/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175330836 | CMS |
| Janssen Biotech, Inc. | $167.94 | 01/31/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175328584 | CMS |
| Janssen Biotech, Inc. | $124.99 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175330330 | CMS |
| Janssen Biotech, Inc. | $575.00 | 01/10/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175331247 | CMS |
| Janssen Biotech, Inc. | $825.00 | 01/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175327669 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,340.00 | 01/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206352945 | CMS |
| Janssen Biotech, Inc. | $825.00 | 01/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175327150 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,238,974.25 | 131 |
| PY2024 | Principal investigator | $258,496.46 | 16 |
| PY2022 | Principal investigator | $34,879.90 | 3 |
| PY2021 | Principal investigator | $41,759.43 | 5 |
| PY2020 | Recipient | $1,800.00 | 2 |
| PY2020 | Principal investigator | $45,906.75 | 3 |
| PY2019 | Recipient | $20,750.00 | 1 |
| PY2019 | Principal investigator | $59,030.29 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
131 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $610.92 | 12/17/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998523 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $239.76 | 12/17/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998525 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $17.52 | 12/17/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998527 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,381.48 | 12/16/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792311 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,171.00 | 12/15/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792307 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,690.10 | 12/15/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,191.00 | 12/15/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430564 |
| Principal investigator 1 | PFIZER INC. | $544.00 | 12/11/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,683.00 | 12/04/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430433 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,171.32 | 12/03/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792299 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,171.32 | 12/03/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792301 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,960.18 | 12/03/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792303 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49,945.50 | 12/03/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792305 |
| Principal investigator 1 | Genentech, Inc. | $1,816.00 | 12/01/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211556692 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,930.43 | 11/30/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998513 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,930.43 | 11/30/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998515 |
| Principal investigator 1 | PFIZER INC. | $3,895.00 | 11/27/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711898 |
| Principal investigator 1 | Genmab A/S | $3,548.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926331 |
| Principal investigator 1 | Genmab A/S | $4,000.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926335 |
| Principal investigator 1 | Genmab A/S | $1,500.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926338 |
| Principal investigator 1 | Genmab A/S | $2,800.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926341 |
| Principal investigator 1 | Genmab A/S | $1,500.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926345 |
| Principal investigator 1 | Genmab A/S | $20,000.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926349 |
| Principal investigator 1 | Genmab A/S | $3,548.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926364 |
| Principal investigator 1 | Genmab A/S | $4,000.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926368 |
| Principal investigator 1 | Genmab A/S | $1,500.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926371 |
| Principal investigator 1 | Genmab A/S | $2,800.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926376 |
| Principal investigator 1 | Genmab A/S | $1,500.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926380 |
| Principal investigator 1 | Genmab A/S | $20,000.00 | 11/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center Cherry Hill | A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06) | No dispute reported | 06/30/2026 | 1235926383 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $135.76 | 11/19/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998517 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $79.92 | 11/19/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998519 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5.84 | 11/19/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998521 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,299.00 | 11/13/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792295 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $837.00 | 11/13/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792297 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,853.00 | 11/10/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430547 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 10/27/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430587 |
| Principal investigator 1 | Amgen Inc. | $7,756.00 | 10/23/2025 | Non-covered Recipient Entity WASHINGTON UNIVERSITY | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors | No dispute reported | 06/30/2026 | 1246651966 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,610.00 | 10/23/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430877 |
| Principal investigator 1 | PFIZER INC. | $544.00 | 10/20/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711832 |
| Principal investigator 1 | PFIZER INC. | $408.00 | 10/20/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711838 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,762.00 | 10/17/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792293 |
| Principal investigator 1 | AstraZeneca UK Limited | $38,800.00 | 10/15/2025 | Non-covered Recipient Entity SWEDISH HEALTH SERVICES | a phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell lung cancer whose disease has progressed on prior osimertinib treatment tropion lung15 | No dispute reported | 06/30/2026 | 1185543701 |
| Principal investigator 1 | PFIZER INC. | $11,306.59 | 10/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711834 |
| Principal investigator 1 | PFIZER INC. | $1,335.00 | 10/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228711836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,683.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430489 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,238.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,683.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430646 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,585.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,643.00 | 10/06/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430912 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $61,395.64 | 09/30/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998499 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,259.00 | 09/29/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792291 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,644.00 | 09/22/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430771 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,170.00 | 09/05/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430569 |
| Principal investigator 1 | Eli Lilly and Company | $33,800.00 | 08/29/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS | No dispute reported | 06/30/2026 | 1187873769 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $67.88 | 08/26/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998507 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $19.98 | 08/26/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998509 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.46 | 08/26/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,102.00 | 08/20/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430710 |
| Principal investigator 1 | Genentech, Inc. | $289.80 | 08/05/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211556682 |
| Principal investigator 1 | PFIZER INC. | $9,299.00 | 08/04/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228787098 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $101.82 | 07/28/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998501 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.94 | 07/28/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998503 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $4.38 | 07/28/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,992.00 | 07/24/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430404 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $37,514.40 | 07/02/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) | No dispute reported | 06/30/2026 | 1185543699 |
| Principal investigator 1 | PFIZER INC. | $2,019.76 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228777832 |
| Principal investigator 1 | PFIZER INC. | $14,419.63 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228785425 |
| Principal investigator 1 | PFIZER INC. | $16,548.60 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228790240 |
| Principal investigator 1 | PFIZER INC. | $12,891.56 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228791581 |
| Principal investigator 1 | PFIZER INC. | $680.00 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228791889 |
| Principal investigator 1 | PFIZER INC. | $680.00 | 06/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228792488 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $373.34 | 06/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998491 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $79.92 | 06/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998493 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $182.50 | 06/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998495 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $13.14 | 06/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998497 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430846 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 06/20/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430831 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $58,977.00 | 06/18/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1236000172 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 06/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430428 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 06/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $608.00 | 06/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430918 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,585.00 | 06/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430975 |
| Principal investigator 1 | Genentech, Inc. | $400.00 | 06/12/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211556665 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 06/12/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228755917 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 06/11/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228743599 |
| Principal investigator 1 | PFIZER INC. | $58,735.00 | 06/09/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228778566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,585.00 | 05/30/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,299.00 | 05/22/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,409.00 | 04/18/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430799 |
| Principal investigator 1 | PFIZER INC. | $50,900.00 | 04/07/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228778717 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $271.52 | 03/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998485 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $159.84 | 03/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998487 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11.68 | 03/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998489 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $48,856.38 | 03/25/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1236000170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,683.00 | 03/24/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 03/24/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430756 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 03/24/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430859 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $128,194.87 | 03/21/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1236000168 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,409.00 | 03/20/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430484 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,294.00 | 03/10/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430505 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,761.00 | 03/10/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,098.00 | 03/10/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430999 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,880.00 | 03/07/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792285 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,294.00 | 03/07/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792287 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $544.00 | 03/07/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792289 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,683.00 | 03/07/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430417 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,585.00 | 03/07/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430670 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $33.94 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998477 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $19.98 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998479 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $37.44 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998481 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.46 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998483 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $401.81 | 02/25/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1236000174 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228755118 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 02/25/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228755556 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 02/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228756119 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 02/24/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228756169 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,570.00 | 02/20/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430369 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $562.00 | 02/13/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220792283 |
| Principal investigator 1 | Genentech, Inc. | $289.80 | 01/28/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | No dispute reported | 06/30/2026 | 1211556658 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $34.98 | 01/27/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998473 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7.98 | 01/27/2025 | Non-covered Recipient Entity Swedish Cancer Institute Treatment Center-Swedish First Hill Campus | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220998475 |
| Principal investigator 1 | Eli Lilly and Company | $3,699.77 | 01/27/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187872589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,006.70 | 01/23/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430734 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $25,900.00 | 01/22/2025 | Covered Recipient Teaching Hospital Swedish Medical Center | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1236000166 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 01/22/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228754614 |
| Principal investigator 1 | PFIZER INC. | $47,181.76 | 01/21/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228754934 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,877.00 | 01/20/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. | No dispute reported | 06/30/2026 | 1175430883 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 01/09/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228755553 |
| Principal investigator 1 | PFIZER INC. | $23,590.88 | 01/08/2025 | Non-covered Recipient Entity Swedish Cancer Institute | A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228754929 |
| Principal investigator 1 | Eli Lilly and Company | $597,391.20 | 01/07/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187873895 |